| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
Immunization with several encephalitogenic myelin peptides causes experimental autoimmune encephalomyelitis (EAE), resembling variety types of multiple sclerosis (MS).
Noting that immunizing SJL/J mice with overlapping myelin proteolipid protein (PLP) residues 136-150 and 139-151 could induce quite different diseases ; monophasic EAE by PLP136-150 and relapsing EAE by PLP139-151, we found the non-genetic factors to maintain remission of EAE as follows : A) the hierarchy of the encephalitogenic peptide itself, which means that the more dominant peptide possessed the capacity to develop acute EAE, the less relapse and re-induction of EAE were occurred, and B) CD4^+CD25^+ regulatory T cells (Treg) induced in the lymphnodes during remission phase, which is characterized by maintenance at high level and by content of the highly potent Treg expressing both CD69 and CD103 (=DP-Treg). This DP-Treg can keep the property of Treg due to the low expression of IL-6R, nevertheless it shares some signatures with Th17, a pathogenic cause of EAE and MS, and may conduct regulatory function in situ.
Furthermore, such regulation could be observed even under non-inflammatory condition, indicating the possibility of a potent and a safe autoimmune vaccination.
|
